Vijaya Diagnostic Centre Limited share price
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics; radiology services, such as CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, and gastroenterology; and advance radiology service comprising nuclear medicine, positron emission tomography CT, and MRI-3T services. It also provides health checkups and home sample collection services, as well as test services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.Read more
- Market Cap₹ 14,231 Cr.
- Current Price₹ 1,381.70
- High / Low₹ 1,594 / 848
- Stock P/E76.0
- Book Value₹ 93
- Dividend Yield0.14 %
- ROCE19.1 %
- ROE19.70 %
- Face Value₹ 1.0
More figures (10)
- EPS (TTM)₹ 18.19
- Price / Book14.85
- OPM30.1 %
- Debt / Equity0.44
- Sales growth (3Y)21.0 %
- Profit growth (3Y)26.6 %
- Promoter holding53.5 %
- EV / EBITDA38.7
- Beta0.36
- All-time high₹ 1,594
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| VIJAYA | -3.94% | -2.18% | +35.57% | +30.23% | +37.87% | +35.61% | +19.19% |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Vijaya Diagnostic Centre Limited is in the Diagnostics & Research industry (Healthcare), with a market value of ₹14,231 crore.
- It trades at 76.0 times its last 12 months' earnings and 14.8 times book value.
- Revenue grew 21.0% a year over the last 3 years, profit 26.6% a year.
- Return on equity was 19.7% and return on capital employed 19.1% in the latest year.
- Debt was 0.44 times shareholders' equity.
- The share price is 13.3% below its 52-week high and up 37.9% over one year.
- Promoters and insiders hold about 53.5%; institutions about 39.4%.
Pros
AI- Strong return on equity: 19.7% on average over the last 3 years.
- Sales have grown 21.0% a year over the last 3 years.
- Profit has grown 26.6% a year over the last 3 years.
- Latest quarter (Jun 2026): sales up 23% and profit up 38% from a year ago.
- Institutional (FII + DII) holding has risen by 3.4 points over 3 years.
Cons
AI- Promoter holding has fallen by 2.41 points over 3 years, to 52.46%.
- Trades at 14.8 times its book value.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited provides diagnostic services for patients in India. The company offers laboratory services, including clinical pathology, microbiology, haematology, serology, histopathology, cytogenetics, biochemistry, and molecular diagnostics; radiology services, such as CT scan, magnetic resonance imaging (MRI) scan, ultrasound, X-ray, cardiology, and gastroenterology; and advance radiology service comprising nuclear medicine, positron emission tomography CT, and MRI-3T services. It also provides health checkups and home sample collection services, as well as test services. Vijaya Diagnostic Centre Limited was founded in 1981 and is based in Hyderabad, India.
- Employees
- 2,507
- Head office
- Hyderabad
- NSE industry
- Healthcare
Peer comparison
HealthcareHealthcareDiagnostics & Research
Part ofNifty 500Nifty Smallcap 250
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Vijaya Diagnostic Centre | 1,381.70 | 76.0 | 14,231 | 0.14 | 53 | 37.61 | 231 | 22.83 | 19.1 | 19.7 | 14.85 | 30.1 | 0.44 | 53.48 | 814 | 21.0 |
| 2. | Dr. Lal PathLabs | 1,859.90 | 57.4 | 31,100 | 1.06 | 171 | 27.24 | 798 | 19.10 | 25.7 | 21.6 | 12.38 | 37.1 | 0.08 | 54.70 | 2,763 | 11.1 |
| 3. | Sai Life Sciences | 1,389.40 | 82.1 | 29,521 | 0.00 | 73 | -16.98 | 554 | -4.35 | 18.1 | 15.1 | 11.83 | 21.9 | 0.12 | 36.28 | 2,137 | 21.3 |
| 4. | Syngene International | 386.10 | 70.3 | 15,518 | 0.33 | -9 | -104.91 | 736 | -27.70 | 8.3 | 6.6 | 3.21 | 15.4 | 0.09 | 52.82 | 3,611 | 5.4 |
| 5. | Metropolis Healthcare | 530.35 | 54.6 | 11,002 | 0.38 | 57 | 25.76 | 450 | 16.62 | 15.7 | 13.4 | 7.27 | 18.1 | 0.15 | 47.82 | 1,646 | 12.8 |
| 6. | Thyrocare Technologies | 485.25 | 44.0 | 7,723 | 1.91 | 51 | 34.06 | 240 | 24.34 | 33.8 | 28.8 | 13.19 | 24.9 | 0.09 | 51.18 | 829 | 16.7 |
| 7. | Suraksha Diagnostic | 306.70 | 44.6 | 1,597 | 0.16 | 13 | 40.00 | 88 | 20.75 | 14.7 | 14.1 | 6.50 | 17.9 | 0.53 | 61.97 | 310 | 17.7 |
| Median: 7 Co. | 530.35 | 57.4 | 14,231 | 0.33 | 53 | 27.24 | 450 | 19.10 | 18.1 | 15.1 | 11.83 | 21.9 | 0.12 | 52.82 | 1,646 | 16.7 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Profit & Loss
Consolidated figures in ₹ croreStandalone figures in ₹ crore /
Projection — your assumptions
Starts from the last four reported quarters (TTM) and applies the figures you enter; growth is pre-filled with the company's own 3-year sales growth. This is a what-if calculator for illustration, not a forecast, estimate or recommendation.
Related party transactions
Related-party transactions are dealings with promoters, directors, subsidiaries and associates. Companies disclose them to the exchanges every half-year and in detail in the notes to their annual report.
- Related Party TransactionsVijaya Diagnostic Centre Limited has informed the Exchange about related Party Transactions29-May-2023
- Related Party TransactionVijaya Diagnostic Centre Limited has informed the Exchange about related party transaction for the period ended September 202224-Nov-2022
- Related Party TransactionVijaya Diagnostic Centre Limited has informed the Exchange about related party transaction for the period ended March 202210-Jun-2022
- Related Party TransactionsVijaya Diagnostic Centre Limited has informed the Exchange about related Party Transactions06-Dec-2021
Full details: notes to the Financial Year 2026 annual report (related party disclosures).
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| 462 | 459 | 548 | 681 | 814 | 857 | |
| YOY Sales Growth % | -0.68% | 19.29% | 24.39% | 19.49% | ||
| 259 | 277 | 327 | 408 | 477 | 495 | |
| Material Cost % | 15% | 13% | 12% | 12% | 12% | 12% |
| Employee Cost % | 15% | 17% | 16% | 16% | 16% | 16% |
| Other Expenses % | 25% | 30% | 31% | 31% | 31% | 30% |
| Operating Profit | 204 | 182 | 221 | 273 | 337 | 362 |
| OPM % | 44% | 40% | 40% | 40% | 41% | 42% |
| 13 | 14 | 21 | 18 | 21 | 22 | |
| Exceptional items | -2 | -1 | ||||
| Interest | 16 | 21 | 24 | 27 | 33 | 37 |
| Depreciation | 53 | 62 | 57 | 71 | 92 | 96 |
| Profit before tax | 147 | 114 | 159 | 193 | 233 | 251 |
| 25% | 25% | 25% | 26% | 26% | 25% | |
| Current tax | 40 | 28 | 33 | 41 | 51 | |
| Deferred tax | -3 | 1 | 6 | 8 | 9 | |
| 111 | 85 | 120 | 144 | 173 | 187 | |
| Minority share | 1 | 1 | 1 | 1 | ||
| Profit to shareholders | 110 | 85 | 119 | 143 | 173 | 187 |
| YOY Profit Growth % | -23.01% | 40.41% | 20.19% | 20.30% | ||
| EPS in Rs | 10.76 | 8.29 | 11.62 | 13.95 | 16.81 | 18.23 |
| Dividend Payout % | 12% | 9% | 7% | 12% |
Compounded Sales Growth
- 3 Years:
- 21%
- TTM:
- 20%
Compounded Profit Growth
- 3 Years:
- 27%
- TTM:
- 24%
Stock Price CAGR
- 5 Years:
- 19%
- 3 Years:
- 36%
- 1 Year:
- 38%
Return on Equity
- 4 Years:
- 19%
- Last Year:
- 20%
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| 451 | 450 | 525 | 627 | 765 | 807 | |
| YOY Sales Growth % | -0.29% | 16.78% | 19.45% | 22.05% | ||
| 251 | 271 | 313 | 375 | 443 | 460 | |
| Material Cost % | 15% | 13% | 12% | 13% | 12% | 12% |
| Employee Cost % | 15% | 17% | 16% | 16% | 16% | 16% |
| Other Expenses % | 25% | 30% | 31% | 31% | 30% | 30% |
| Operating Profit | 200 | 179 | 212 | 253 | 322 | 347 |
| OPM % | 44% | 40% | 40% | 40% | 42% | 43% |
| 13 | 15 | 21 | 19 | 25 | 27 | |
| Exceptional items | -2 | -1 | ||||
| Interest | 16 | 21 | 24 | 25 | 31 | 34 |
| Depreciation | 52 | 61 | 55 | 65 | 80 | 84 |
| Profit before tax | 144 | 111 | 152 | 181 | 236 | 255 |
| 25% | 25% | 25% | 26% | 25% | 25% | |
| Current tax | 39 | 28 | 32 | 39 | 50 | |
| Deferred tax | -3 | 1 | 6 | 8 | 8 | |
| 108 | 83 | 115 | 135 | 178 | 193 | |
| YOY Profit Growth % | -23.01% | 37.69% | 17.81% | 32.07% | ||
| EPS in Rs | 10.60 | 8.16 | 11.21 | 13.16 | 17.33 | 18.74 |
| Dividend Payout % | 12% | 9% | 8% | 12% |
Compounded Sales Growth
- 3 Years:
- 19%
- TTM:
- 22%
Compounded Profit Growth
- 3 Years:
- 29%
- TTM:
- 33%
Stock Price CAGR
- 5 Years:
- 19%
- 3 Years:
- 36%
- 1 Year:
- 38%
Return on Equity
- 4 Years:
- 19%
- Last Year:
- 20%
Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 535 | 647 | 789 | 947 |
| Borrowings | 248 | 259 | 320 | 423 |
| 61 | 66 | 155 | 127 | |
| Trade payables | 28 | 33 | 33 | 38 |
| Minority interest | 2 | 3 | 3 | |
| Current liabilities | 66 | 73 | 163 | 124 |
| Total Liabilities | 853 | 983 | 1,274 | 1,507 |
| 550 | 615 | 802 | 977 | |
| Gross block | 822 | 935 | 1,190 | 1,444 |
| Accumulated depreciation | 272 | 321 | 388 | 467 |
| Goodwill & intangibles | 8 | 140 | 141 | 140 |
| CWIP | 34 | 13 | 79 | 48 |
| 270 | 356 | 393 | 482 | |
| Inventories | 2 | 5 | 5 | 5 |
| Trade receivables | 9 | 16 | 15 | 21 |
| Cash & equivalents | 24 | 22 | 13 | 40 |
| Current assets | 276 | 211 | 307 | 322 |
| Total Assets | 853 | 983 | 1,274 | 1,507 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 165 | 183 | 224 | 271 | |
| Profit for the year | 85 | 119 | 144 | 173 |
| Working capital changes | 9 | -1 | -7 | -17 |
| Direct taxes paid | -26 | -34 | -40 | -52 |
| -110 | -142 | -182 | -174 | |
| Fixed assets purchased | -125 | -88 | -96 | -183 |
| Fixed assets sold | 0 | 3 | 3 | 3 |
| Investments purchased | -80 | -209 | -151 | -82 |
| Investments sold | 89 | 291 | 59 | 81 |
| -42 | -45 | -52 | -69 | |
| Repayment of borrowings | -1 | |||
| Interest paid | -0 | -21 | -24 | -31 |
| Dividends paid | -10 | -10 | -10 | -21 |
| Net Cash Flow | 13 | -4 | -9 | 27 |
| Free Cash Flow | 40 | 95 | 129 | 88 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROE | — | 15.5% | 19.8% | 19.7% | 19.7% |
| ROCE | — | 16.9% | 19.9% | 19.6% | 19.1% |
| Operating margin | — | 26.2% | 29.9% | 29.8% | 30.1% |
| Net margin | — | 18.4% | 21.7% | 21.1% | 21.3% |
| Debt / equity | — | 0.45 | 0.39 | 0.40 | 0.44 |
| Current ratio | — | 4.17 | 2.90 | 1.89 | 2.60 |
| Debtor days | — | 8 | 11 | 8 | 9 |
| Inventory days | — | 13 | 29 | 21 | 19 |
| Days payable | — | 172 | 184 | 143 | 145 |
| Cash conversion cycle | — | -151 | -144 | -114 | -117 |
| Working capital days | — | 167 | 92 | 78 | 89 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 52.46%
- FIIs 10.66%
- DIIs 32.50%
- Public 4.38%
| % | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 54.87% | 54.06% | 53.93% | 53.91% | 53.91% | 53.05% | 52.63% | 52.60% | 52.60% | 52.51% | 52.51% | 52.46% |
| 19.95% | 20.09% | 20.08% | 18.14% | 17.54% | 19.36% | 19.56% | 18.27% | 15.10% | 13.38% | 11.66% | 10.66% | |
| Foreign portfolio investors (Cat. I) | 19.74% | 19.87% | 19.84% | 17.71% | 16.95% | 16.03% | 16.40% | 14.97% | 12.54% | 11.13% | 9.77% | 9.13% |
| Foreign portfolio investors (Cat. II) | 0.21% | 0.22% | 0.24% | 0.43% | 0.59% | 3.33% | 3.16% | 3.30% | 2.56% | 2.25% | 1.88% | 1.54% |
| 19.83% | 20.80% | 21.49% | 23.46% | 24.63% | 23.72% | 24.07% | 25.34% | 28.59% | 29.93% | 31.61% | 32.50% | |
| Mutual funds | 19.41% | 20.37% | 20.90% | 22.87% | 23.97% | 23.67% | 23.55% | 24.80% | 27.98% | 29.06% | 30.66% | 31.44% |
| Insurance companies | 0.14% | 0.21% | 0.44% | 0.50% | 0.55% | 0.01% | 0.48% | 0.51% | 0.51% | 0.51% | 0.57% | 0.53% |
| Alternative investment funds | 0.27% | 0.22% | 0.15% | 0.08% | 0.10% | 0.04% | 0.04% | 0.03% | 0.11% | 0.36% | 0.38% | 0.52% |
| 5.35% | 5.05% | 4.50% | 4.49% | 3.92% | 3.87% | 3.74% | 3.79% | 3.71% | 4.18% | 4.23% | 4.38% | |
| Retail (up to ₹2 lakh) | 4.63% | 4.38% | 3.98% | 3.94% | 3.43% | 3.42% | 3.24% | 3.20% | 3.14% | 3.47% | 3.49% | 3.55% |
| NRIs | 0.25% | 0.23% | 0.17% | 0.17% | 0.16% | 0.17% | 0.13% | 0.22% | 0.23% | 0.23% | 0.24% | 0.26% |
| Bodies corporate | 0.37% | 0.32% | 0.26% | 0.29% | 0.25% | 0.20% | 0.14% | 0.14% | 0.13% | 0.17% | 0.30% | 0.32% |
| No. of Shareholders | 66,204 | 66,724 | 62,415 | 62,258 | 60,952 | 66,891 | 62,115 | 58,994 | 57,784 | 62,946 | 67,251 | 70,966 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Vijaya Diagnostic Centre
No single fund or institution holds more than 1%.
As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 31.44% of the company. Shareholders below 1% are not named in the filing.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Vijaya Diagnostic Centre Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter Ending September 30, 2026.06-Oct-2026
- Trading WindowVijaya Diagnostic Centre Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Shareholders meetingVijaya Diagnostic Centre Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the company has informed the E…26-Sep-2026
- Shareholders meetingVijaya Diagnostic Centre Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 202624-Sep-2026
- Press ReleaseVijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "100% acquisition of integrated diagnostic business undertaki…11-Sep-2026
- Outcome of Board MeetingVijaya Diagnostic Centre Limited has informed the Exchange regarding Outcome of Board Meeting held on September 11, 2026. (Approval for execution of Business Transfer Agreement ("…11-Sep-2026
- AppointmentVijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr Venkata Naresh Yallapragada as Other of the company w.e.f. September 02, 2026.02-Sep-2026
- Change in ManagementVijaya Diagnostic Centre Limited has informed the Exchange about change in Management02-Sep-2026
- Copy of Newspaper PublicationVijaya Diagnostic Centre Limited has informed the Exchange about Copy of Newspaper Publication27-Aug-2026
- Change in Company Secretary/Compliance OfficerVijaya Diagnostic Centre Limited has informed the Exchange about resignation of Company Secretary/Compliance Officer26-Aug-2026
- ResignationVijaya Diagnostic Centre Limited has informed the Exchange regarding Resignation of Mrs. Naga Vasudha Tadepalli as Company Secretary & Compliance Officer of the company w.e.f. Aug…26-Aug-2026
- Resignation of Director/KMP/SMPVijaya Diagnostic Centre Limited has informed the Exchange about Resignation of Director/KMP/SMP26-Aug-2026
Annual reports
- Financial Year 202626-AUG-2026
- Financial Year 202513-AUG-2025
- Financial Year 202414-AUG-2024
- Financial Year 2023
- Financial Year 2022
Credit ratings
None filed recently.
Concalls & investor meets
- General UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about General Updates - Investor Presentation - 100% Acquisition of integrated diagnostic business undertaking of Arya W…11-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Schedule of meet02-Sep-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Transcript10-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Link of Recording07-Aug-2026
- Investor PresentationVijaya Diagnostic Centre Limited has informed the Exchange about Investor Presentation06-Aug-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Schedule of meet29-Jul-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Schedule of meet28-Jul-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Schedule of meet09-Jun-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Transcript13-May-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesVijaya Diagnostic Centre Limited has informed the Exchange about Schedule of meet12-May-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 16 Sep 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Mar 2026
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Vijaya Diagnostic Centre Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the Quarter Ending September 30, 2026.NSE filing · 06-Oct-2026
- Trading WindowVijaya Diagnostic Centre Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- Shareholders meetingVijaya Diagnostic Centre Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the company has informed the E…NSE filing · 26-Sep-2026
- Shareholders meetingVijaya Diagnostic Centre Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 24, 2026NSE filing · 24-Sep-2026
- Press ReleaseVijaya Diagnostic Centre Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "100% acquisition of integrated diagnostic business undertaki…NSE filing · 11-Sep-2026
- Outcome of Board MeetingVijaya Diagnostic Centre Limited has informed the Exchange regarding Outcome of Board Meeting held on September 11, 2026. (Approval for execution of Business Transfer Agreement ("…NSE filing · 11-Sep-2026
- AppointmentVijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr Venkata Naresh Yallapragada as Other of the company w.e.f. September 02, 2026.NSE filing · 02-Sep-2026
- Change in ManagementVijaya Diagnostic Centre Limited has informed the Exchange about change in ManagementNSE filing · 02-Sep-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Vijaya Diagnostic Centre Limited
What is the share price of Vijaya Diagnostic Centre Limited today?
What is the market cap of Vijaya Diagnostic Centre Limited?
What is the P/E ratio of Vijaya Diagnostic Centre Limited?
Is Vijaya Diagnostic Centre Limited a good investment?
How can I buy Vijaya Diagnostic Centre Limited shares?
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.
